

**Crinetics Pharmaceuticals, Inc.**  
**10222 Barnes Canyon Road, Bldg. #2**  
**San Diego, CA 92121**

August 27, 2019

**VIA EDGAR**

Ms. Mary Beth Breslin  
Branch Chief  
Office of Healthcare and Insurance  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: Crinetics Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**

**File No. 333-233246**

Dear Ms. Breslin:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Crinetics Pharmaceuticals, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on Thursday, August 29, 2019, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.

Very truly yours,

CRINETICS PHARMACEUTICALS, INC.

By: /s/ Marc J.S. Wilson

Marc J.S. Wilson  
Chief Financial Officer

cc: R. Scott Struthers, Ph.D., Crinetics Pharmaceuticals, Inc.  
Cheston J. Larson, Esq., Latham & Watkins LLP  
Matthew T. Bush, Esq., Latham & Watkins LLP  
Kevin C. Reyes, Esq., Latham & Watkins LLP